

Citeline系列产品概要 (07/2018)

Robert Wu
Client Service Executive
客服与产品培训师





内容

Citeline Next Generation版本

- Citeline系列一览
- Citeline各产品之概要
- Next Generation版本之新功能
- 现场产品演示

Citeline.Informa.com

Citeline客服支持

- 分析师咨询服务 (*Ask the Analyst*)
- 产品培训及客服团队支持

Citeline系列一览

专注于R&D领域的全方位咨询服务

Trialtrove	最全面、准确、及时的临床试验信息来源
Trialpredict	历史及可预测的临床受试者募集与临床时间数据来源
Sitetrove	扩展对潜在临床研究人员了解与范围，以便更好地选择目标国家或地区进行临床研究
Pharmaprojects	使用最值信赖的药物研发数据库，全面追踪全球范围内的R&D管线

- 综合临床试验、药物、临床研究人员，以及临床研究机构或地区等信息
- 一次性注册，随时随地进行使用
- 数据实时更新，并设有高效自动邮件提醒系统

提供完整与准确的R&D数据

Citeline Next Gen – 提供世界级的服务水平与最快、最强大、最便捷的操作平台，并且含有各领域专家的专业分析

- 35年+ 服务经验
- 285,500+ 临床试验信息
- 240+ 适应症（共8个主要疾病领域）
- 415,000+ 临床研究人员信息
- 157,000+ 临床试验地点信息
- 40,000+ 特别信息来源
- 72,000+ 药物报告
- 184个国家或地区
- 注：Pharmaprojects则包含14个疾病领域内的1400+适应症

内容范围涵盖整个公共领域


主要信息来源 – 目前引用超过4万个信息来源并持续增长

- 超过70个来自各国或地区的临床试验注册机构（如：clinicaltrials.gov, EUCTR, Japic）
- 其他临床试验资讯来源（如：申办方注册信息、合作机构、主要医疗中心）
- 超过4800个企业信息（全面涵盖管线、新闻报道、投资者，以及其他网页）
- 所有主要医疗会议（超过250个会议）
- 新闻资源、投资者演讲、美国证监会文件，以及公司年度报告等
- 各国医疗及卫生机构的官方网页
- 医学杂志及论坛
- USAN与INN lists, eMolecules, ChemSpider, & ChemIDplus
- 网上资源，如：Gene（前身为EntrezGene）、PubMed，以及Espacenet等

引用额外信息来源以确保全面市场情报覆盖

- 那些看似无多关联的信息资源也能提供具有价值的见解：
 - 研究中心网站
 - 社区医院网站
 - 大学研究规章/IRB审核批准目录
 - 患者权益相关网站
 - 调访研究报告 (Primary Research)

Total Cited Sources by Therapeutic Area



- 内容持续更新
- 所有资料均提供完整出处信息，以确保查证的透明性

Citeline的高级索引系统与独有内容为您节省大量的数据收集时间

Trialtrove:

- ✓ 临床试验时间数据
- ✓ 临床试验时间预测数据
- ✓ 特定患者群体
- ✓ 临床试验结果
- ✓ 临床研究方案
- ✓ 申办方种类 (如: 政府或行业赞助的临床试验)
- ✓ 按药物批准状态查询临床试验
- ✓ 含有生物标记的临床试验
- ✓ 含PGX的临床试验
- ✓ 更多

Pharmaprojects:

- ✓ R&D市场趋势数据 (1995年至今)
- ✓ 伴随诊断 (Companion Diagnostic)
- ✓ 罕见疾病药物
- ✓ 按生物靶区查询药物
- ✓ 各种监管申请信息
 - ✓ 快径资格
 - ✓ 孤儿药状态
 - ✓ 产品注册
 - ✓ 适应症扩展
- ✓ 更多

- ▶ 作为严格把关的一部分, 我们的专业分析师团队手动添加各种疾病、监管及市场信息, 以分类代码的形式纳入到相应的药物与临床试验资料库内。
- ▶ 该高级索引系统简化了搜索过程, 以便能瞬间查询所需信息。
- ▶ **Citeline简化了整个过程, 也同时为您节省了时间!**

Sitetrove:

- ✓ 高资历临床研究人员
- ✓ 热点分布图 (Heat maps)
- ✓ 临床研究地点搜索
- ✓ 按邮政编码查询地点
- ✓ 临床研究人员的研究专业
- ✓ 临床研究地点种类
- ✓ 按年份查询临床研究活动更新
- ✓ 更多

Trialtrove概要

Trial Title Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma							Trial Phase III	Trial Status Completed
Sponsorship GSK	Disease Type Renal Cancer	Patient Segment First line, Stage II, Stage III, Stage IV	Start Date July 2010	Treatment Duration 13.8 to 17.8 months	End Date 9/28/2012	Target Accrual 876 (50% of patients from US)	Actual Accrual 927 1110 (ESMO 2012)	Identified Sites 120

Trial Locations US, Global	Drugs Tested Pazopanib Sunitinib	Patient Segments 8844 078,, 200	Trial Timing CTRN12609000392268,	Patient Accrual and Site Details
Trial Tag/Attribute Post-Marketing Commitment, Registration, Biomarker/Efficacy, PGX - Biomarker Identification/Evaluation	Protocol IDs COMPARZ, CTO#101268, GSK, VEG108844, GU 59, IEO S450/109, JapicCTI-090687, MKSCC-08-089, NCRN044, NCT00720941, NCT01147822, PGLAXO020/08-049, TrialtroveID-094588, UKCRN ID 5082,			Outcome Details Head-to-head study of GSK's Votrient (pazopanib) vs sunitinib in advanced renal cell carcinoma meets primary endpoint.

Trial Attribute Details	Protocol IDs	Trial Outcome Details
This study compares pazopanib compared to sunitinib in the treatment of subjects with locally advanced or metastatic renal cell carcinoma who have received no prior systemic therapy. Subjects will be randomized in a 1:1 ratio to receive either 800mg pazopanib or 50mg sunitinib daily for 4 weeks followed by 2 weeks off treatment. Patients' stratification is based on Karnofsky performance score.	ed RCC who have received no prior systemic therapy. Locally advanced or metastatic renal cell carcinoma who have received no prior systemic therapy. Locally advanced or metastatic renal cell carcinoma who have received no prior systemic therapy.	Head-to-head study of GSK's Votrient (pazopanib) vs sunitinib in advanced renal cell carcinoma meets primary endpoint.

Additional Information	Additional information about secondary outcome measures
Patients Eligible for Study: 18 years and older	History or clinical evidence of central nervous system (CNS) metastases (unless have previously-treated CNS metastases and meet all 3 of the following criteria are: are asymptomatic, have had no evidence of active CNS metastases for >=6 months prior to enrolment, and have no requirement for steroids or enzyme-inducing anticonvulsants)

Inclusion Criteria:	Additional information about secondary outcome measures
Diagnosis of renal cell carcinoma with measurable disease by CT or MRI Received no prior systemic therapy (including but not limited to: bevacizumab, mTOR inhibitor, sunitinib, pazopanib, or other tyrosine kinase inhibitors) Locally advanced or metastatic renal cell carcinoma Measurable disease by CT or MRI Karnofsky performance scale status of >=70 Age >=18 years A female is eligible to enter and participate in this study if she is of: non-childbearing or agrees to use adequate contraception. Adequate organ system function Total serum calcium concentration <12.0mg/dL Left ventricular ejection fraction >= lower limit of institutional reference range	History or clinical evidence of central nervous system (CNS) metastases (unless have previously-treated CNS metastases and meet all 3 of the following criteria are: are asymptomatic, have had no evidence of active CNS metastases for >=6 months prior to enrolment, and have no requirement for steroids or enzyme-inducing anticonvulsants) Clinically significant gastrointestinal abnormalities including, but not limited to: malabsorption syndrome, major resection of the stomach or small bowel that could affect the absorption of study drug, active peptic ulcer disease, known intraluminal metastatic lesion/s with suspected bleeding, Inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with symptoms of obstruction, or intra-abdominal abscess


Primary Endpoint/Outcome measures/objectives Progression free survival	Other Endpoint/Outcome measures/objectives Overall survival, Quality of Life (QoL), Health-related Quality of Life (HRQoL), Patient-reported Outcomes (PROs), Biomarker analysis,
Detail R&D Intelligence casts a wider net across the entire public domain	
Trial Results Results: Patient characteristics were balanced. The upper bound of the 95% CI for PFS by IRC was <1.25, indicating pazopanib is non-inferior to sunitinib. Differences in 11 of 14 QoL domains were small but statistically significant, all favoring pazopanib. Conclusions: Pazopanib has similar efficacy to sunitinib with a differentiated safety and QoL profile.	

Last Modified 03/20/2014 **Last Full Review** 10/05/2013

- Supporting URLs**
- <http://clinicaltrials.gov/show/NCT00082433>
 - <http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm>
 - http://www.anzctr.org.au/trial_view.aspx?id=83718
 - <http://www.cancer.gov/clinicaltrials/search/view?cdrid=601947&version=Health...>
 - <http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=601947&version=Health...>
 - http://www.canjurol.com/pdfs/clinicaltrials/OpenTrials_Feb09.pdf
 - <http://www.centerwatch.com/clinicaltrials/listings/studydetails.aspx?Study...>
 - <http://www.clinicaltrials.jp/user/cteDetail.jsp?clinicalTrialId=1686&language...>
 - <http://www.esmo.org/fileadmin/media/pdf/2012/press/ESMO-2012-Press-Conferen...>
 - http://www.gla.ac.uk/media/media_43569_en.pdf
 - <https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002102-1...>
 - <https://www.protonet.fccc.edu/cgi-bin/protoco...>

Trialtrove vs. clinicaltrials.gov
您少用了多少信息资源？

不含在Clinicaltrials.gov数据库却能在
Trialtrove中查询的信息资源数量



数据取自2017年1月

Trialpredict概要

何为Trialpredict?

实际的各阶段临床试验用时数据

- ▶ 超过58300个临床试验的实际患者募集用时数据
- ▶ 超过106000个临床试验的实际治疗期用时数据

何处获取Trialpredict数据?

时间数据可在Trialtrove内查询 – <https://citeline.informa.com>

- ▶ 临床试验报告

Trial Timing	
Start Date	Oct 1, 2007 - Actual
Enrollment Duration (Mos.)	35.1 [Actual]
Enrollment Close Date	Sep 1, 2010 - Actual
Treatment Duration (Mos.)	60 [Actual]
Primary Completion Date	Jun 30, 2014 - Anticipated
Primary Endpoints Reported	Dec 6, 2011 - Actual
Pts/Site/Mo	0.25

- ▶ Trialtrove检索结果页面 – Trial timing一栏

<input checked="" type="checkbox"/> Trial timing		
<input checked="" type="checkbox"/> Start Date	<input checked="" type="checkbox"/> Start Date Type	<input checked="" type="checkbox"/> Enrollment Duration (Mos.)
<input checked="" type="checkbox"/> Enrollment Duration Type	<input checked="" type="checkbox"/> Enrollment Close Date	<input checked="" type="checkbox"/> Enrollment Close Date Type
<input checked="" type="checkbox"/> Treatment Duration (Mos.)	<input checked="" type="checkbox"/> Treatment Duration Type	<input checked="" type="checkbox"/> Primary Completion Date
<input checked="" type="checkbox"/> Primary Completion Date Type	<input checked="" type="checkbox"/> Primary Endpoints Reported Date	<input checked="" type="checkbox"/> Primary Endpoints Reported Date Type
<input checked="" type="checkbox"/> Pts/Site/Mo		

- ▶ 用于收集竞争对手信息，包括实际和预期时间数据

Trialpredict如何能帮助我？

申办方经常低估完成临床试验的所需时间。

临床试验的延误将会影响整个临床发展计划。

Trialpredict的临床试验时间数据能使您更有效地计划、控制预算、监测和评估临床研究项目。

评估市场竞争格局

- 将您的临床研究方案与竞争对手进行比较
- 使用历史基准数据建立您的临床研究项目时间表或评估竞争对手的研发项目
- 评估潜在人选或授权许可合作机遇

为您的临床研究或研发项目作出规划

- 评估合作方的受试者募集与临床研究所需时间预测
- 更有效地规划应对竞争对手临床研究的成果
- 更有效地规划与评估完整临床研究项目的所需时间
- 实际评估您所关注的临床试验受试者募集情况及时间表
- 实际调整处于“救援模式”（rescue mode）临床试验的时间表

调整预算

- 使用历史数据进行估算并找出最佳或最差成本方案
- 使用时间预测数据对进行中的临床试验项目的成本预算作出调整

Sitetrove概要

临床研究困境 – 为何使用Sitetrove?

- ▶ 65%的制药行业R&D预算（每年超500亿美元）被用于各类临床研究
- ▶ 95%的临床试验项目无法按时完成
- ▶ 主要原因：未能达到受试者募集预期目标
- ▶ 超过70%的临床试验被至少延误一个月
- ▶ 高成本：每月约120万美元的额外支出
- ▶ 最大限度地优化受试者募集将能节省大量成本




何为Sitetrove?

临床研究人员的数据库 –

- ▶ 所有已知的临床研究人员会根据临床研究经验进行实时评估：
 - 超过40万名临床研究人员（全球范围）
 - 超过160个国家及地区
- ▶ 联系信息
- ▶ FDA警告或检查
- ▶ 临床研究经验
- ▶ 谁正在参与竞争对手的临床试验研究?
- ▶ 识别出现役的临床研究人员
- ▶ 临床研究人员的优先次序排列（按专业及经验而定）

Sitetrove全球范围研究人员分布图



临床研究人员的首选次序排列

寻找有经验与高潜力的临床研究人员

临床研究资历与适用性：

- ▶ 综合临床研究经验
- ▶ 从事疾病领域的临床研究经验
- ▶ 以往经历相似临床研究的经验
 - 相似受试者人群数量、靶点、临床阶段等

近期活动或潜在能力：

- ▶ 过去12个月内是否完成过临床研究？
- ▶ 最近是否有完成受试者募集的预期目标？



Pharmaprojects概要

药物报告里含有什么信息？

- 研发方与授权许可方
- 所有适用适应症以及最高临床阶段
- 历史事件 – 追踪重大事件，如：研发状态变化、孤儿药申请获批、上市
- 药物作用机制与靶点
- 药物在全球范围内哪里上市或获批
- 药物授权许可状态
- 孤儿药状态
- 化学成分信息 (origin, chemical name, chemical structure etc)
- 临床试验信息
- 临床前信息

药物报告里含有什么信息？（续）

孤儿药状态

Renal cell carcinoma

USA; for the treatment of renal cell carcinoma (FDA orphan Drug List, 6 Nov 2003, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=172903).

Peritoneal carcinoma

USA; for the treatment of primary peritoneal carcinoma (FDA orphan Drug List, 2 Nov 2010, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=317810).

Stomach cancer

USA; for the treatment of stomach cancer in combination with a platinum and 5-FU or capecitabine (FDA Orphan drug list, 11 Nov 2013, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=294409).

快径许可

Cancer, cervical

USA; it has priority review status for the treatment of persistent, recurrent or metastatic cervical cancer (Press release, Genentech, 14 Jul 2014, <http://www.gene.com/media/press-releases/14569/2014-07-14/fda-grants-genentechs-avastin-priority-r>).

Cancer, ovarian

USA; it has priority review status for the treatment of women with recurrent platinum-resistant ovarian cancer (Press release, Genentech, 21 Jul 2014, <http://www.gene.com/media/press-releases/14570/2014-07-21/fda-grants-genentechs-avastin-priority-r>).


FDA警告

USA; increased risk of ovarian failure, osteonecrosis of the jaw (ONJ), venous thromboembolic event (VTE) and bleeding. The warning also includes tainted compounded Avastin led to serious eye infections, with some of those cases leading to blindness (Scrip Intelligence, 6 Oct 2011, <http://www.scripintelligence.com/policyregulation/US-FDA-warns-of-ovarian-failure-ONJ-with-Avastin-use-322039>).

EU; a contraindication warning on the EU label for untreated brain metastases was removed following updated safety data (Press release, Roche, 31 Mar 2009).

USA; a warning was added to its US label recommending discontinuation in patients developing reversible posterior leucoencephalopathy syndrome (Scrip Daily Online, 26 Sep 2006, S00934820).

趋势分析工具 - 历史R&D数据变化动态图



	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V
1	World Status	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
2	Suspended						2	3	1	1	3	4	2		1							
3	Launched				1	3	3	3	4	4	7	7	8	10	12	13	13	12	12	15	19	22
4	Registered									1		1	2	1					1		1	
5	Pre-registration				1		1	1		1	1	1	3	1	1	2	1		3	3	2	1
6	Phase III	3	3	6	4	4	3	6	7	9	6	8	7	6	7	10	12	15	17	18	23	31
7	Phase II	7	8	13	15	24	27	27	27	25	19	16	19	20	21	29	38	46	51	65	71	77
8	Phase I	2	8	7	14	5	9	9	11	11	13	15	12	12	20	29	30	39	48	51	53	54
9	Preclinical	25	26	27	26	17	14	16	25	29	55	56	50	63	77	65	61	77	114	114	121	132

Pharmaprojects之用处

商业发展

- ▶ 识别潜在授权许可机遇
- ▶ 分析药物发展历史
- ▶ 发现新的治疗策略

竞争对手情报

- ▶ 通过公司、疾病、药物作用机制、或靶点等各种领域，获取全面竞争市场格局
- ▶ 分析重大市场事件，如：药物下市、上市、获批，以及孤儿药状态

R&D

- ▶ 哪些药物有相似化学结构或机制
- ▶ PPAR antagonists在哪个适应症内进行过研究？

Next Generation Citeline 全新功能

视觉逻辑搜索 (Visual Boolean Search)

进行动态交互式搜索

- 凭直觉建立复杂的搜索
- 调整搜索并同步查看筛选经过

快速获取所需的信息

提高搜索结果的准确性，
即便是不常用的用户也可
轻易做到

随意尝试各种搭配和开发
新的见解

The screenshot illustrates a multi-step visual Boolean search process. At the top, a search bar shows '272,706 trials' (circled in red) with options to 'View related: Trials | Investigators | Organizations' and buttons for 'Table' and 'Map'. Below this, a series of stacked panels show the search being refined. The first panel shows 'Trial Phase is II or Trial Phase is III'. The second panel adds 'Therapeutic Area is Infectious Disease'. The third panel adds 'Trial Region is North America'. The fourth panel adds 'Trial Status is Open'. The final panel at the bottom shows '229 trials' (circled in red) with the same 'View related' and 'Table/Map' options. A large red arrow on the left points from the initial search results down to the final refined results.

视觉逻辑搜索 (Visual Boolean Search)


方便修改，注重逻辑思维

- 指定每个连接词语该如何使用 (is, is not, contains, does not contain)
- 组合词语用于处理复杂逻辑思维
- 使用参数连接词 (and/or) 建立复杂搜索

无须再记住复杂的搜索配搭及结构

实时同步查看与验证检索结果


快速与准确地确认搜索条件，即便是储存或共享的检索



快捷搜索栏

快速查询相关数据

- 输入关键词
- 根据以上词语快速查询可用的搜索结果或搜索参数
- 单个或同时使用关键词检索与过滤搜索
- 搜索全文内容



节省时间

发现意想不到的搜索条件搭配方式
为不常使用的用户简化了检索

动态搜索与筛选

快速、轻松地搜索与筛选结果

- 通过扩展或缩小搜索条件列表轻松地查询结果
- 从列表中选择或通过关键词搜索快速找到搜索条件
- 实时查看查询结果

更快、更精准的搜索方式

对初用者或不常用用户来说更便捷，同时保留了资深用户的需求

Trial	Disease	↑	×
Trial Title	×	Therapeutic Area: Cardiovascular	
Trial Phase	▼	Filter Disease	
Trial Status	Displaying 11 of 158 keywords		
Trial Start Date	Cardiovascular: (N/A)	+	
Therapeutic Area	Cardiovascular: Acute Coronary Syndromes	+	
Disease	Cardiovascular: Arrhythmia	+	
Patient Segment	Cardiovascular: Cardiomyopathy (Under Construction)	+	
MeSH Term	Cardiovascular: Congestive Heart Failure	+	
Protocol/Trial ID	Cardiovascular: Coronary Artery Disease	+	
Location	Cardiovascular: Dyslipidemia	+	
Region	Cardiovascular: Hemostasis/Hemophilia	+	
Country	Cardiovascular: Hypertension	+	
Drug	Cardiovascular: Peripheral Arterial Disease	+	
Therapeutic Class	Cardiovascular: Thrombotic Disorders	+	

大量导入搜索条件

轻松建立复杂的搜索列表

- 输入或上传搜索词列表
- 可用于MeSH、临床研究名称、疾病、患者群体、Protocol或Trial编号、国家等

节省时间

提升可靠性

导出结果后轻松自定义建立新的搜索列表，以便创建新的搜索

MeSH Term: enter multiple keywords

Import from a spreadsheet

Spreadsheets should contain a single column of keywords exactly as they appear in the results table or export document. The file should be in XLS, CSV, or ODF format.

Select file to import from

and/or paste keywords

Separate keywords with line breaks. Keywords should be exactly as they appear in the results table or export document.

Keyword 1
Keyword 2
Etc.

Cancel

Import

自定义视图选择与数据导出

自行定制观看结果方式

- 添加、删减或重新排列搜索结果栏目
- 导出所有或已选的栏目数据
- 向右滑动查看更多信息栏目
- 导出所有或已选信息
- 选择以表格或地图方式查看
- 搜索结果栏目内进一步筛选

3,482 trials View related: Trials | [Investigators](#)

Table Map

Column counts 50 results Show/Hide columns Export

Trial Phase	Disease	Trial Title	Protocol/Trial ID	Trial Status
II	Infectious Disease: HIV	10493 - MK-0518 Intensification and HDAC Inhibition in Depletion of Resting CD4+ T Cell HIV Infection	10493, CID 0704, NCT00576290, NCT00614458, NIH R01 A164074, P30 AI50410, P30AI050410, R01 A164074, R01 A145297, R01A1064074, RR00046, TrialTroveID-081414, U01 A125868, U01A1067854, U01A1125868	Terminated
II	Infectious Disease: HCV	12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.	NCT00069511, TrialTroveID-012721, UT-231B-02:01	Completed
III	Infectious Disease: HIV	1592U89 Open-Label Protocol for Pediatric Patients With HIV Infection	1592U89, NCT00072385, CMAA-2007, CMAA-2007, CMAA-2007	Completed
II	Infectious Disease: Respiratory Infections	3-arm Randomized Controlled Trial of the Effect of an Oral Antiviral on Adults		

3,482 trials View related: Trials | [Investigators](#)

Map Satellite

Arctic Ocean Arctic Ocean

Greenland

Canada

USA

North Atlantic Ocean

South Pacific Ocean

South Atlantic Ocean

South Africa

Madagascar

Indian Ocean

Indonesia

Papua New Guinea

Australia

Trial Title

Show items with value that:

contains

Apply

A Molecular Biology and Immunology Study of the Effect of RN163L in Children With Ependymoma and Diffuse Intrinsic Pontine Glioma

A Multicenter Multinational Study of the Effect of K/PD Dose-finding Study of Oral Netupitant Given With

节省时间 – 无须导出内容再查看数据，也无须返回至筛选结果界面

提升准确性 – 通过同时查看关键数据、搜索条件，以及能随时调整搜索

资料连接

快速浏览相关记录

- 直接从临床研究名称右键点击另开网页，并直达相应资料
- 使用Navigation快速跳到所需信息

The screenshot displays a web application interface for clinical trial management. On the left, a navigation menu lists various trial details: Primary Endpoint, Other Endpoint, Patient Population, Inclusion Criteria, Exclusion Criteria, Patient Gender, Target Accrual, Actual Accrual, Disposition of Patients, Patient Age, Treatment Plan, Study Keywords, Study Design, and Trial Tag/Attribute. The main content area shows a list of 8 trials with columns for Trial Title, Protocol/Trial ID, Trial Phase, Trial Status, Sponsor, and a Select checkbox. A context menu is open over the first trial, offering options like 'Open link in new tab', 'Open link in new window', 'Open link in incognito window', 'Save link as...', 'Copy link address', and 'Inspect'. An inset window provides a detailed view of a trial's 'Treatment Plan' and 'Trial Notes'. The 'Treatment Plan' section includes 'Study Design' (Interventional, Single Group Assignment, Open Label) and 'Arms' (Experimental: combination nivolumab and ipilimumab). The 'Trial Notes' section shows dates and completion estimates. A 'Feedback' button is visible in the bottom right corner of the inset window.

Trial Title	Protocol/Trial ID	Trial Phase	Trial Status	Sponsor	Select
A Phase II Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Advanced Non-small Cell Lung Cancer	2000020343, NCT03262779, TrialTroveID-307769	II	Open	Bristol-Myers Squibb, Yale U	<input type="checkbox"/>
A Phase II Study of Pembrolizumab and Ipilimumab in Patients With Advanced Non-Small Cell Lung Cancer	NCT03256136, TrialTroveID-	II	Planned	Bristol-Myers Squibb, Mass General Hospital	<input type="checkbox"/>
A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer	BTCRC-LUN15-029, NCT03083808, TrialTroveID-297861	II	Open	Merck & Co./Merck Sharp &	<input type="checkbox"/>

保存与分享


随时随地使用

Legacy版本

- 自动保存最近搜索
- 无法对已存搜索起名
- 除了重要搜索外无法选择保存


Next Gen版本

- 只保存您觉得重要的搜索
- 可以对已存搜索起名
- 同一地方管理Trialtrove与Sitetrove的已存搜索



随意切换Legacy或Next Generation版本

根据需要随意切换



Citeline更新时间表*

Next Generation Citeline功能更新路线图

Q3 2018

Sitetrove

Watches & Alerts
(检索追踪及自动邮件提醒功能)

Trialtrove & Sitetrove

Interactive Maps
(地图功能)

Trialtrove

Trial Timing Dashboard
临床项目时间图表

Pharmaprojects &

Trialtrove

BizInt数据导出功能

公司信息

趋势

化学结构检索

Q4 2018

退役Legacy平台 (旧版)

ALL-
Pharmaprojects/
Trialtrove/Sitetrove

Sitetrove

Pharmaprojects

Trialtrove

*上述为2018年7月之决策, 更新内容及时间可根据现实改变

现场演示

Next Gen版本现场演示

“ 点击

<https://Citeline.informa.com>

注册并登陆 ”

客服支持

分析师咨询服务 (Ask the Analyst)

The screenshot shows the Citeline website interface. At the top right, the 'Ask the Analyst' button is circled in red. Below the search bar, there are buttons for 'Clear', 'Share', 'Save', and 'Open/manage'. The main content area shows a table of trial results with columns for Trial Phase, Disease, Trial Title, and Protocol/Trial ID. A 'Feedback' button is circled in red on the table.

Trial Phase	Disease	Trial Title	Protocol/Trial ID
I	NA: CT.gov	" An Open Label Pilot Study Evaluating Safety and Evidence of Therapeutic Effect of IV Admin of 2-0, 3-0 Desulfated Heparin, Treatment of Exacerbation of Protein Losing Enteropathy (PLE) Associated With Single Ventricle Palliative Surgery"	NCT01161641, PGX-ODSH-2009
III	NA: CT.gov	" Endarterectomy Combined With Optimal Medical Therapy"	10, NCT0284109

请点击使用“Ask The Analyst”服务询问内容、商业或业务、搜索建议等相关问题，并点击“Feedback”键向我们提供有关Next Generation Citeline的意见反馈。

Citeline客服团队 – clientservices@citeline.com

全面售后客服支持

- 主要联系点
- 常见答疑
- 产品登录管理
- 个性化技术支持
- 数据导出与产品使用建议或培训
- 客户反馈与建议

无限制的专门产品培训

- 定制大型产品培训
- 互动培训或特定领域的培训
 - 基本产品培训
 - 进阶产品培训
 - 高级产品培训（包含特殊领域辅导）
- 录制培训视频、快速辅导视频与常见问题
- 现场产品培训（须10名或以上的参加人士）

感谢!